Thirty-six patients (29 males and 7 females) undergoing open-heart surgery received one of three different dose regimens of lorazepam. All received a weight-related oral dose (2 mg, 3 mg or 4 mg) pre-operatively for night sedation. Twenty-four patients had an additional weight-related dose (2 mg, 3 mg or 4 mg intravenously) either as part of the induction (12 patients) or just prior to connection of the heart-lung machine (12 patients). Plasma concentrations of lorazepam were measured 20 minutes after induction, immediately before bypass, 30 and 60 on bypass and 30 minutes after bypass. Only when additional intravenous lorazepam was given prior to connection to the heart-lung machine were plasma lorazepam concentrations obtained compatible with complete amnesia.
We therefore studied the effect of CPB on plasma levels of lorazepam using three different dose regimens in order to evaluate a method of administration which would produce levels compatible with amnesia. METHOD After receiving ethical committee approval, patients undergoing heart surgery with cardiopulmonary bypass were admitted to the study. All were interviewed pre-operatively and informed consent was obtained. Those with a history of allergy to benzodiazepines or ingestion of any drugs in this group within the previous 10 days were excluded. The patients were allocated to three groups, according to a randomised balanced design, all receiving oral lorazepam on the pre-operative night for sedation. Group 1 patients received no further lorazepam. All other patients additionally received intravenous lorazepam, either as part of the induction via a peripheral venous cannula (Group 2), or 10 minutes prior to connection to the heart-lung machine via an internal jugular cannula (Group 3). The dose of lorazepam administered on each occasion was related to the body weight as follows: <60 kg, 2 mg; 60-80 kg, 3 mg; >80 kg, 4 mg.
The anaesthetic technique was otherwise standardised. Premedication was with omnopon and scopolamine according to weight. The patients were induced with phenoperidine (0.05 mg/kg), pancuronium (0.1 mg/kg) and thiopentone (1 mg/kg), and ventilated with nitrous oxide and oxygen with a fresh gas flow for positive pressure ventilation to maintain normocarbia. An infusion of Hartmann's solution (10 mllkg) was administered prior to bypass. The oxygenator, a Bentley BOS 10, was primed with Hartmann's solution (1150 ml), Haemaccel (150 ml) and dextrose 50070 (200 ml), and stored blood was then added to replace operative loss.
Blood samples (5 ml) for measurement of plasma lorazepam were collected at the following times: 1. 20 minutes after induction, 2. immediately before bypass, 3. 30 minutes on bypass, 4. 60 minutes on bypass (or at the end of bypass if the duration was less than 60 minutes), and 5. 30 minutes after bypass. Samples 1 and 5 were collected via a peripheral venous cannula, and samples 2 to 4 via an arterial line. The blood was centrifuged, and the separated plasma stored at -20°C until analysis. The extraction technique used has been described previously. 12 Briefly, 500 ~l of plasma standard or sample, to which prazepam internal standard had been added, were buffered to pH 7.4. The drugs were extracted into diethyl ether 1 ml by gentle mixing for 10 'minutes. Following centrifugation, the ether was evaporated to dryness under air at 60°C. The residue was reconstituted in 50~l of n-butyl acetate, of which 2 ~l portions were subjected to gas liquid chromatography with electron capture detection under the conditions described by Greenblatt et al. l3 
RESULTS
Thirty-six patients (three groups of 12) participated in the study. They comprised 29 males and 7 females, with a mean age of 50 years (SD 11 years). Their details are shown in Tables 1 and 2 .
The mean plasma lorazepam concentration at each time point for the three groups of patients are shown in Table 3 . In Group 1 patients, mean lorazepam concentrations were always less than 20 ~g/l. In Group 2 patients, mean lorazepam concentrations although initially high, fell rapidly to below 30 ~g/l by the time bypass was initiated. In Group 3 patients, mean lorazepam concentrations exceeded 45 ~g/l during the bypass and immediate post-bypass periods. Connection to the heart-lung machine caused an average 27% fall in plasma lorazepam concentration, whilst disconnection was followed by an average 17% rise in this measurement. Despite the current popularity of narcoticbased techniques in anaesthesia for open-heart surgeryl4 there is continuing discussion regarding their use 15 and concern about the high risk of awareness. 1 -3 To avoid awareness volatile agents can be used during cardiopulmonary bypass. 16 However, there are problems when drugs such as halothane are added into the gas-line from an anaesthetic vaporiser. Inefficiency of some oxygenators may lead to inhibition of drug-to-blood transfer. Haemodilution and hypothermia cause changes in the blood-gas partition coefficient leading to alteration in anaesthetic transport and behaviour. 17 With hypothermia the blood-gas coefficient may rise as much as 40-50070. Finally the low gas flows may not reliably allow accurate vaporisation of halothane particularly when they fall below 4 litres/min. 16 For these reasons the eventual concentration of halothane available is very variable. Further, a major study comparing the two techniques 18 confirmed that halothane anaesthesia was associated with a significantly lower arterial pressure level during CPB.
Lorazepam has been used widely both as night sedation and premedication in general surgery, and has been shown to compare favourably with diazepam, producing better sedation and anterograde amnesia. 19 ,20 The effects of lorazepam are longer-lasting than Group 2 Group 3 All patients The amnesic effect of orally administered lorazepam lasts 4 to 6 hours. It is reported that the maximal effects of lorazepam are at plasma concentrations above 30 ng/ml while at less than 10 ng/ml there is little action of the drug. 7 Aaltonen and colleagues 24 who have recommended the use of lorazepam for openheart surgery administered 4 mg intravenously to 5 patients one hour before CPB. The plasma levels on bypass were consistently below 15 ng/ml during perfusion but rose to above 30 ng/ml in the post-bypass period. The lorazepam concentrations observed in this study on the morning following the initial dose were similar to previous reports. 7 ,25,26 Only those patients in Group 3 had plasma concentrations which were consistently within the therapeutic range suggested to be associated with maximal effects of lorazepam. 7 Group 1 patients never achieved these concentrations during the operation. While Group 2 patients initially had concentrations within this range, these had fallen markedly by the time bypass was commenced. Both Group 2 and Group 3 patients had had a recent intravenous dose of lorazepam, and their plasma drug concentrations would be falling rapidly during the course of the operation. However, Group 1 patients had not received any lorazepam for more than 12 hours and since the elimination 60 minutes on bypass 12(5) 27 (7) 47 (18) Post-bypass 14 (6) 34 (13) 49 (18) half-life of lorazepam is in the region of 8 to 32 hours (mean 15 hours), no appreciable difference would be expected between adjacent concentration measurements. 7 ,25,26 The effect of connection to the heart-lung machine can therefore be studied in Group I, While connection to the heart-lung machine produced a mean 271170 decrease (range 43% decrease to 29% increase) in lorazepam concentration, disconnection resulted in a mean 17% increase (range 83% increase to 331170 decrease) in this measurement. This is in line with previous reports of propranolol and cephalothin in similarly designed experiments. IO , 11 The reasons for these observations are only speculative at the present time. Although consistent with blood dilution due to the added volume of the pump prime, and shrinkage in blood volume after surgery, these changes alone are insufficient to explain the magnitude of the response in some patients. However, if the distribution of drug between blood plasma and red blood cells is significantly different from unity, then these dilutional effects will be exaggerated. Alterations in protein binding secondary to heparinisation may be contributary for some drugs, but unlikely in the case of 10razepamY The effects of temperature changes and alterations in liver blood flow, together with redistribution of drug from tissues not perfused during bypass, for example lungs, skin and muscle, will also affect drug concentrations to some extent following termination of bypass.
Our study shows that because of changes in drug distribution during cardiopulmonary bypass, the administration of an intravenous dose of lorazepam (2 to 4 mg) prior to connection to the heart-lung machine may be necessary to ensure the maintenance of plasma drug concentration compatible with maximal effective action of lorazepam.
